Is the shielding effect of cholecalciferol in SARS CoV-2 infection dependable? An evidence based unraveling

Shaik Lahoor Basha; Sake Suresh; V V Ashok Reddy; S P Surya Teja

doi:10.1016/j.cegh.2020.10.005

Is the shielding effect of cholecalciferol in SARS CoV-2 infection dependable? An evidence based unraveling

Clin Epidemiol Glob Health. 2021 Jan-Mar:9:326-331. doi: 10.1016/j.cegh.2020.10.005. Epub 2020 Oct 21.

Authors

Shaik Lahoor Basha¹, Sake Suresh², V V Ashok Reddy³, S P Surya Teja⁴

Affiliations

¹ Department of Medical Affairs, HealthMinds, Bengaluru, Karnataka, 560038, India.
² Department of General Medicine, Andaman & Nicobar Health Services, Port Blair, 744104, India.
³ Department of Emergency Medicine, Pushpagiri Institute of Medical Sciences, Tiruvalla, Kerala, India.
⁴ Health Minds Consulting Pvt Ltd, Bengaluru, India.

Abstract

Despite being announced as a global health concern and emergency in January by WHO, designing specific treatment for SARS-CoV-2 is still a summit yet to be conquered. Currently, many drugs are being tested in the clinical scenario and vitamins play a significant role in therapeutic management. Based on the available evidence, we postulate that maintaining normal vitamin D₃ levels may reduce severity, mortality risk of COVID-19. This review elucidates the alarming need for randomized clinical trials to determine the role of vitamin D in patient prognosis in COVID-19 infection and on latitude bases epidemiological outcome.

Keywords: Cathelicidin; Diabetes; Hypertension; Influenza; Latitude; Pneumonia.

Publication types

Review